每周调整胰岛素输注设置的12周24/7门诊人工胰腺:对糖化血红蛋白和低血糖的影响
这项单臂、非对照、多中心门诊临床试验评估新型自适应人工胰腺(AP)系统治疗1型糖尿病(T1D)成人患者12周的效果。29例完成试验,糖化血红蛋白(HbA1c)从AP启用时的7.0±0.8%降至12周后的6.7±0.6%(变化-0.3,95%CI -0.5至-0.2,P<0.001),日间和夜间低血糖时间均减少,无方案相关严重不良事件。
要点
- 12周自适应AP使HbA1c从7.0±0.8%降至6.7±0.6%(-0.3,95%CI -0.5至-0.2,P<0.001)。
- 日间低血糖时间从5.0%降至1.9%(-3.1,95%CI -4.1至-2.1,P<0.001)。
- 夜间低血糖时间从4.1%降至1.1%(-3.1,95%CI -4.2至-1.9,P<0.001)。
核心结论
- 使用新型自适应AP系统可显著降低HbA1c和低血糖。
研究设计与样本
- 研究为门诊、单臂、非对照、多中心临床试验,为期12周,纳入30例1型糖尿病成人患者。
主要发现
- 29例患者完成试验;HbA1c从AP启用时的7.0±0.8%降至12周后的6.7±0.6%(变化-0.3,95%CI -0.5至-0.2,P<0.001)。
- 与传感器增强泵(SAP)导入期相比,日间低血糖时间从5.0%降至1.9%(变化-3.1,95%CI -4.1至-2.1,P<0.001),夜间从4.1%降至1.1%(变化-3.1,95%CI -4.2至-1.9,P<0.001)。
- 碳水化合物系数初期调整幅度较大,此后变化很小;基础胰岛素则全程持续调整。
- 约10%的调整建议被人工覆盖。
- 无方案相关严重不良事件。
临床怎么用
- 原文结论指出,使用该新型自适应AP系统可显著降低HbA1c和低血糖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. RESEARCH DESIGN AND METHODS: Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials. RESULTS: Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (-0.3, 95% CI -0.5 to -0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (-3.1, 95% CI -4.1 to -2.1, P < 0.001) and overnight from 4.1 to 1.1% (-3.1, 95% CI -4.2 to -1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events. CONCLUSIONS: Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
引用
- Dassau E, Pinsker JE, Kudva YC, et al. Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. Diabetes Care. 2017. PMID: 29030383. doi:10.2337/dc17-1188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。